文献速递临床试验与 GCP流行病学与生物统计

医用大麻或大麻素治疗慢性非癌性与癌性疼痛:随机临床试验的系统综述与Meta分析

Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials.
PubMed 文献 · BMJ · 2021-09-08

该系统综述与Meta分析纳入32项随机临床试验共5174例成人慢性疼痛患者,评估医用大麻或大麻素相比非大麻素对照的获益与危害。结果显示非吸入医用大麻可能小幅改善疼痛缓解、躯体功能与睡眠质量,但伴随多种短暂不良反应。

要点

  • 非吸入医用大麻可能小幅增加疼痛缓解达最小重要差异的患者比例(RD 10%)。
  • 口服医用大麻对躯体功能与睡眠质量有很小改善,但未改善情绪、角色或社会功能。
  • 口服医用大麻增加头晕、嗜睡、恶心、呕吐等短暂不良反应风险。

核心结论

  • 中至高确定性证据表明非吸入医用大麻或大麻素对慢性疼痛患者的疼痛缓解、躯体功能和睡眠质量有微小至非常微小的改善,同时伴随多种短暂不良反应。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE等数据库及试验注册库至2021年1月。
  • 纳入32项随机临床试验共5174例成人患者,其中29项比较医用大麻或大麻素与安慰剂。
  • 给药方式为口服(n=30)或局部外用(n=2),随访时长1至5.5个月。
  • 临床人群包括慢性非癌性疼痛(n=28)和癌性疼痛(n=4)。

主要发现

  • 相比安慰剂,非吸入医用大麻可能小幅增加疼痛缓解达最小重要差异(10cm VAS上1cm)的患者比例,模型风险差10%(95%CI 5%至15%),基于加权均数差-0.50cm(95%CI -0.75至-0.25cm,中等确定性)。
  • 口服医用大麻对躯体功能有非常微小改善,达SF-36躯体功能量表最小重要差异(100分制10分)的模型风险差4%(95%CI 0.1%至8%),加权均数差1.67分(95%CI 0.03至3.31,高确定性)。
  • 口服医用大麻对睡眠质量有小幅改善,达10cm VAS上1cm最小重要差异的模型风险差6%(95%CI 2%至9%),加权均数差-0.35cm(95%CI -0.55至-0.14cm,高确定性)。
  • 口服医用大麻未改善情绪、角色或社会功能(高确定性)。
  • 中等确定性证据显示口服医用大麻可能小幅增加短暂认知障碍(RD 2%,95%CI 0.1%至6%)、呕吐(RD 3%,95%CI 0.4%至6%)、嗜睡(RD 5%,95%CI 2%至8%)、注意力受损(RD 3%,95%CI 1%至8%)和恶心(RD 5%,95%CI 2%至8%)风险,但不增加腹泻。

临床怎么用

  • 对于慢性疼痛患者,可考虑非吸入医用大麻或大麻素以小幅改善疼痛、躯体功能和睡眠质量,但需权衡短暂不良反应风险。
  • 处方时应告知患者可能出现头晕、嗜睡、恶心、呕吐、注意力受损等不良反应,并监测随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the benefits and harms of medical cannabis and cannabinoids for chronic pain. DESIGN: Systematic review and meta-analysis. DATA SOURCES: MEDLINE, EMBASE, AMED, PsycInfo, CENTRAL, CINAHL, PubMed, Web of Science, Cannabis-Med, Epistemonikos, and trial registries up to January 2021. STUDY SELECTION: Randomised clinical trials of medical cannabis or cannabinoids versus any non-cannabis control for chronic pain at ≥1 month follow-up. DATA EXTRACTION AND SYNTHESIS: Paired reviewers independently assessed risk of bias and extracted data. We performed random-effects models meta-analyses and used GRADE to assess the certainty of evidence. RESULTS: A total of 32 trials with 5174 adult patients were included, 29 of which compared medical cannabis or cannabinoids with placebo. Medical cannabis was administered orally (n=30) or topically (n=2). Clinical populations included chronic non-cancer pain (n=28) and cancer related pain (n=4). Length of follow-up ranged from 1 to 5.5 months. Compared with placebo, non-inhaled medical cannabis probably results in a small increase in the proportion of patients experiencing at least the minimally important difference (MID) of 1 cm (on a 10 cm visual analogue scale (VAS)) in pain relief (modelled risk difference (RD) of 10% (95% confidence interval 5% to 15%), based on a weighted mean difference (WMD) of -0.50 cm (95% CI -0.75 to -0.25 cm, moderate certainty)). Medical cannabis taken orally results in a very small improvement in physical functioning (4% modelled RD (0.1% to 8%) for achieving at least the MID of 10 points on the 100-point SF-36 physical functioning scale, WMD of 1.67 points (0.03 to 3.31, high certainty)), and a small improvement in sleep quality (6% modelled RD (2% to 9%) for achieving at least the MID of 1 cm on a 10 cm VAS, WMD of -0.35 cm (-0.55 to -0.14 cm, high certainty)). Medical cannabis taken orally does not improve emotional, role, or social functioning (high certainty). Moderate certainty evidence shows that medical cannabis taken orally probably results in a small increased risk of transient cognitive impairment (RD 2% (0.1% to 6%)), vomiting (RD 3% (0.4% to 6%)), drowsiness (RD 5% (2% to 8%)), impaired attention (RD 3% (1% to 8%)), and nausea (RD 5% (2% to 8%)), but not diarrhoea; while high certainty evidence shows greater increased risk of dizziness (RD 9% (5% to 14%)) for trials with <3 months follow-up versus RD 28% (18% to 43%) for trials with ≥3 months follow-up; interaction test P=0.003; moderate credibility of subgroup effect). CONCLUSIONS: Moderate to high certainty evidence shows that non-inhaled medical cannabis or cannabinoids results in a small to very small improvement in pain relief, physical functioning, and sleep quality among patients with chronic pain, along with several transient adverse side effects, compared with placebo. The accompanying BMJ Rapid Recommendation provides contextualised guidance based on this body of evidence. SYSTEMATIC REVIEW REGISTRATION: https://osf.io/3pwn2.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Wang L, Hong PJ, May C, et al. Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ. 2021. PMID: 34497047. doi:10.1136/bmj.n1034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。